title: Quantitative estimation of myocardial salvage after primary percutaneous transluminal coronary angioplasty in patients with angiographic no reflow.
abstract: Angiographic Thrombolysis in Myocardial Infarction (TIMI) flow grade <or=2 after primary percutaneous transluminal coronary angioplasty (PTCA), defined as angiographic no reflow, predicts poor left ventricular functional recovery and survival in patients with acute myocardial infarction (MI). To determine the relation between angiographic coronary flow and myocardial salvage in the acute phase of MI, serial technetium-99m tetrofosmin imaging was performed before, immediately after and 1 month after PTCA in 117 patients. Angiographic no reflow was observed in 23 patients (20%; group 1), while 94 patients did not have angiographic no reflow (group 2). Although there was no significant difference in the defect score before PTCA between the two groups (group 1, 14.4+/-5.7; group 2, 13.5+/-4.6), the defect score immediately after PTCA in group 1 was significantly higher than that in group 2 (group 1, 12.8+/-5.1; group 2, 8.9+/-4.6; P<0.0001). A significantly smaller change in the defect score after PTCA (before minus immediately after PTCA) was observed in group 1 as compared with group 2 (group 1, 1.7+/-2.0; group 2, 4.5+/-2.9; P<0.0001). Twenty patients in group 1 (87%) had impaired myocardial reperfusion (<4 change in the defect score immediately after PTCA), as compared with 36 patients (38%) in group 2; this difference was significant (chi(2)=17.5, P<0.0001). The sensitivity, specificity and accuracy of angiographic no reflow in estimating impaired myocardial reperfusion were 36%, 95% and 67%, respectively. Thus, angiographic no reflow is a highly specific, although not sensitive, marker of impaired myocardial reperfusion immediately after primary PTCA.
authors.affiliation: The Second Department of Internal Medicine, Cardiovascular Centre, Kansai Medical University, 10-15 Fumizono-cho, 570-8507 Moriguchi, Osaka, Japan. nakamurs@takii.kmu.ac.jp
authors.forename: Seishi
authors.initials: S
authors.lastname: Nakamura
authors.forename: Kazuya
authors.initials: K
authors.lastname: Takehana
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Sugiura
authors.forename: Kengo
authors.initials: K
authors.lastname: Hatada
authors.forename: Shinichi
authors.initials: S
authors.lastname: Hamada
authors.forename: Junko
authors.initials: J
authors.lastname: Asada
authors.forename: Reisuke
authors.initials: R
authors.lastname: Yuyama
authors.forename: Jun
authors.initials: J
authors.lastname: Mimura
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Imuro
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Kurihara
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Fukui
authors.forename: Masato
authors.initials: M
authors.lastname: Baden
authors.forename: Toshiji
authors.initials: T
authors.lastname: Iwasaka
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D017023:Coronary Angiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging* / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000000981:diagnostic imaging* / Q000209:etiology; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000209:etiology
chemical_list: D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C078700:technetium tc-99m tetrofosmin